- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Roundtable Discussion: Rini Reviews Later-Line Immunotherapy and TKI Combinations in Refractory RCC
December 02, 2021
Base on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.
Niraparib Shows Efficacy in Platinum-Sensitive Ovarian Cancer
December 01, 2021
Zai Lab has announced new findings from the phase 3 PRIME trial showing efficacy in progression-free survival in patients with platinum-sensitive ovarian cancer.
Etiglimab/Nivolumab Combination Shows Promise in Solid Tumors
December 01, 2021
The combination elicited a complete response in patient with cervical cancer and a partial response in a patient with ovarian cancer.
Characteristics of the MET Exon 14 Skipping Mutation NSCLC Population
December 01, 2021
Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.
More Research Needed to Support FDA Approval of Plinabulin Plus G-CSF for CIN Prevention
December 01, 2021
The FDA has decided not to approve plinabulin with granulocyte colony-stimulating factor for the prevention of chemotherapy-induce neutropenia until further research is conducted.
Safety Profile of Enfortumab Vedotin in Urothelial Cancers
December 01, 2021
Thomas Powles, MD, MBBS, MRCP, discusses the safety profile of enfortumab vedotin in urothelial cancers as observed in the phase 3 urothelial cancerstrial.
FDA Approves Subcutaneous Daratumumab Triplet for R/R Multiple Myeloma
December 01, 2021
The approval is based on the phase 2 PLEAIDES study, which found the agent had an ORR of 84.8%, with 82.5% of patients still responding after 9 months.
Evolving Treatments Address Challenging AML Subtypes
December 01, 2021
In an interview with Targeted Oncology, Richard M. Stone, MD, discussed challenging subtypes of acute myeloid leukemia and therapies available to treat them.
A Look Back at FDA News from November 2021
December 01, 2021
Here is a look back FDA happenings from November 2021.
Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma
December 01, 2021
A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.
Tailoring Therapy for Patients With mRCC
December 01, 2021
Next steps investigating novel-based therapies for newly diagnosed metastatic renal cell carcinoma.
mRCC: Role of Oncology Nurses in Managing I/O–TKI Adverse Events
December 01, 2021
Advice to oncology nurses who manage patients with metastatic renal cell carcinoma receiving novel-based therapies, including lenvatinib and pembrolizumab.